Armistice Capital’s Kura Oncology KURA Stock Holding History

Armistice Capital’s Portfolio KURA Stock Details KURA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$40.3M	Sell	3,678,000 -58,000	-2%	-$547K	0.49%	32
2026 Q1	$30.4M	Sell	3,736,000 -1,200,000	-24%	-$10.3M	0.54%	33
2025 Q4	$51.3M	Buy	4,936,000 +264,000	+6%	+$2.77M	0.61%	24
2025 Q3	$41.3M	Sell	4,672,000 -1,528,000	-25%	-$10.9M	0.61%	24
2025 Q2	$35.8M	Sell	6,200,000 -372,000	-6%	-$2.28M	0.62%	27
2025 Q1	$43.4M	Buy	6,572,000 +772,000	+13%	+$6.02M	0.65%	32
2024 Q4	$50.5M	Buy	5,800,000 +3,142,000	+118%	+$45.2M	0.69%	29
2024 Q3	$51.9M	Buy	2,658,000 +308,000	+13%	+$6.24M	0.83%	23
2024 Q2	$48.4M	Buy	2,350,000 +302,000	+15%	+$6.21M	0.61%	30
2024 Q1	$43.7M	Sell	2,048,000 -176,000	-8%	-$3.42M	0.58%	28
2023 Q4	$32M	Sell	2,224,000 -12,000	-0.5%	-$118K	0.44%	41
2023 Q3	$20.4M	Buy	2,236,000 +112,000	+5%	+$1.14M	0.31%	56
2023 Q2	$22.5M	Buy	2,124,000 +888,000	+72%	+$10.5M	0.33%	57
2023 Q1	$15.1M	Buy	1,236,000 +164,000	+15%	+$2.05M	0.22%	77
2022 Q4	$13.3M	Buy	+1,072,000	New	+$15.6M	0.23%	66

Other funds holding KURA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ACM

Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

Armistice Capital's KURA Position: Q2 2026 in Review

Armistice Capital reduced its Kura Oncology (KURA) stake by 1.6% in Q2 2026, selling an estimated $547K and leaving 3,678,000 shares worth $40.3M. The position accounts for 0.49% of the portfolio, ranked #32.

Armistice Capital first reported a position in KURA in Q4 2022 and has held it in 15 quarters since. The position peaked at $51.9M in Q3 2024. 220 funds tracked by Wall St. Rank hold KURA as of Q2 2026.

Armistice Capital held 3,678,000 shares of Kura Oncology worth $40.3M as of Q2 2026.
Armistice Capital sold 58,000 Kura Oncology shares in Q2 2026, an estimated $547K.
Kura Oncology made up 0.49% of Armistice Capital's portfolio in Q2 2026, its #32 holding.
Armistice Capital first reported a position in Kura Oncology in Q4 2022 and has held it in 15 quarters since.
Armistice Capital's Kura Oncology position peaked at $51.9M in Q3 2024.
220 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2026.

Based on Armistice Capital's 13F filing for Q2 2026, filed 14 Aug 2026.